Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

4.530 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
From Agenus Inc.
Via Business Wire
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
From Agenus Inc.
Via Business Wire
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
From Agenus Inc.
Via Business Wire
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
From Agenus Inc.
Via Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US
From Agenus Inc.
Via Business Wire
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer
From Agenus Inc.
Via Business Wire
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
From Agenus Inc.
Via Business Wire
Agenus Reports Q1 2025 Financial Results and Key Business Updates
From Agenus Inc.
Via Business Wire
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
From Agenus Inc.
Via Business Wire
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
From Agenus Inc.
Via Business Wire
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
From Agenus Inc.
Via Business Wire
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
From Agenus Inc.
Via Business Wire
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
From Agenus Inc.
Via Business Wire
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
From Agenus Inc.
Via Business Wire
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
From Agenus Inc.
Via Business Wire
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
From Agenus Inc.
Via Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From Agenus Inc.
Via Business Wire
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
From Agenus Inc.
Via Business Wire
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
From Agenus Inc.
Via Business Wire
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
From Agenus Inc.
Via Business Wire
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
From Agenus Inc.
Via Business Wire
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
From Agenus Inc.
Via Business Wire
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
From Agenus Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.